Approximately six months into new ownership Zdravlje A.D. (“Zdravlje”) is proud to announce the signing of a new agreement with Celltrion Healthcare Hungary Kft. (“Celltrion Healthcare”), a leading force in the biopharmaceutical industry. This agreement will make regdanvimab (CT-P59), a monoclonal antibody treatment for COVID-19, available for patients in Serbia and in the ex-Yugoslavia region.